<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">Clin Hypertens</journal-id><journal-title-group><journal-title>Clinical Hypertension</journal-title></journal-title-group><issn pub-type="epub">2056-5909</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28228970</article-id><article-id pub-id-type="pmc">5309991</article-id><article-id pub-id-type="publisher-id">60</article-id><article-id pub-id-type="doi">10.1186/s40885-016-0060-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ki</surname><given-names>You-Jeong</given-names></name><address><email>drkiyou@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Jae-Bin</given-names></name><address><email>cetuximab@naver.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hack-Lyoung</given-names></name><address><email>khl2876@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Woo-Hyun</given-names></name><address><email>woosion@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Hye Yeon</given-names></name><address><email>hymargie@hanmail.net</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jin Yong</given-names></name><address><email>wowjy0426@naver.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chung</surname><given-names>Woo-Young</given-names></name><address><phone>82-2-870-3864</phone><email>chungwy3023@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0302 820X</institution-id><institution-id institution-id-type="GRID">grid.412484.f</institution-id><institution/><institution>Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution/><institution>Seoul National University, College of Medicine, </institution></institution-wrap>Seoul, South Korea </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>23</volume><elocation-id>4</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Endothelium has a function to regulate vascular tone by releasing mediators either vasodilating or vasoconstricting blood vessels. Endothelial dysfunction can be measured conveniently by Reactive Hyperemia Index (RHI) with a peripheral arterial tonometry. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II (AT II) receptor blockers (ARBs) are considered to have beneficial effects on endothelium through inhibition of AT II. This study was performed to compare the effect of ACEIs or ARBs on endothelial function estimated by RHI in hypertensive patients.</p></sec><sec><title>Methods</title><p>Twenty consecutive patients with hypertension (57.9&#x02009;&#x000b1;&#x02009;11.3&#x000a0;years, 60% men) were assigned to receive treatment with ramipril or telmisartan for eight weeks (<italic>n&#x02009;=</italic>&#x02009;10 per group). Blood pressure (BP) and RHI were measured at baseline and after eight weeks treatment.</p></sec><sec><title>Results</title><p>The two groups were similar in terms of demographic and laboratory characteristics. But baseline systolic BP and pulse pressure (PP) were higher in telmisartan group than ramipril group (systolic BP, 159&#x02009;&#x000b1;&#x02009;6.83 vs 150&#x02009;&#x000b1;&#x02009;7.49, <italic>p&#x02009;=</italic>&#x02009;0.028; PP, 75.0&#x02009;&#x000b1;&#x02009;14.0 vs 60.3&#x02009;&#x000b1;&#x02009;12.4, <italic>p&#x02009;=</italic>&#x02009;0.034). In both groups, systolic and diastolic BP decreased significantly after eight weeks treatment (p&#x02009;&#x0003c;&#x02009;0.05 for each). Although PP reduced in both group (ramipril group, 60.3&#x02009;&#x000b1;&#x02009;12.4&#x000a0;mm Hg to 50.4&#x02009;&#x000b1;&#x02009;7.60&#x000a0;mm Hg; telmisartan group, 75.0&#x02009;&#x000b1;&#x02009;14.0&#x000a0;mm Hg to 57.4&#x02009;&#x000b1;&#x02009;15.1&#x000a0;mm Hg), change was statistically remarkable only in telmisartan group. During eight weeks, there was no significant changes of RHI in both groups. There was a positive relationship between decrease of PP after 8&#x000a0;weeks and the improvement of endothelial function only in ramipril group, but not in telmisartan group (ramipril group, <italic>r</italic>&#x02009;=&#x02009;0.671, <italic>p&#x02009;=</italic>&#x02009;0.034; telmisartan group, <italic>r</italic>&#x02009;=&#x02009;&#x02212;0.487, <italic>p&#x02009;=</italic>&#x02009;0.153).</p></sec><sec><title>Conclusions</title><p>Despite PP reduction effect favoring endothelial function, it&#x02019;s not correlated with RHI improvement with telmisartan. These findings suggest telmisartan itself may negatively influence endothelium dependent vasodilatation different from ramipril.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ramipril</kwd><kwd>Telmisartan</kwd><kwd>Endothelial function</kwd><kwd>Reactive hyperemia index</kwd><kwd>Pulse pressure</kwd></kwd-group><funding-group><award-group><funding-source><institution>Korean Society of Hypertension</institution></funding-source><award-id>26-2013-77</award-id><principal-award-recipient><name><surname>Chung</surname><given-names>Woo-Young</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Vascular endothelium is a layer of cells lining the inner surface of vessels, separating the vascular wall from the blood [<xref ref-type="bibr" rid="CR1">1</xref>]. Endothelium is a paracrine, endocrine and autocrine organ that is essential for vascular homeostasis and regulation of vascular tone [<xref ref-type="bibr" rid="CR1">1</xref>]. Endothelium has a function to regulate vascular tone by release of vasodilator and vasoconstrictor substance [<xref ref-type="bibr" rid="CR2">2</xref>]. Healthy endothelium has inhibitory effects on platelet aggregation and adhesion, smooth muscle cell proliferation and leukocyte adhesion [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>An imbalance between endothelium derived relaxing factor and endothelin yields vascular tone dysfunction [<xref ref-type="bibr" rid="CR2">2</xref>]. Endothelial dysfunction is an initiating event in atherosclerotic process and leads to plaque vulnerability, plaque rupture and thrombus formation [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Thus the presence of endothelial dysfunction is a predictor of future cardiovascular events [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Endothelial function can be measured by Reactive Hyperemia Index (RHI) with a peripheral arterial tonometry (PAT) and flow medicated dilatation (FMD) of brachial artery with brachial artery ultrasound scanning (BAUS) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Both PAT and BAUS are validated method for evaluating peripheral endothelial function. Especially PAT is operator non-dependent, the most convenient and non-invasive method. The value of PAT has been validated in many clinical studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Many studies have investigated the effect of AT II receptor blockers (ARBs) on endothelial function assessed by FMD. In a meta-analysis showed that ARBs improved the endothelial function compared with other antihypertensive agents and there was no difference between ARBs and angiotensin-converting enzyme inhibitors (ACEIs) [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Angiotensin II (AT II) regulates endothelial function and promotes endothelial cell apoptosis via reactive oxygen species (ROS) and oxidized low-density lipoprotein (oxLDL) uptake [<xref ref-type="bibr" rid="CR10">10</xref>]. In many studies, ACEIs and ARBs have beneficial effects on endothelium through inhibition of AT II [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Especially, ACEIs could improve vasodilation via decreased levels of AT II, increased levels of nitric oxide (NO) and bradykinin, whereas ARBs does not elevate bradykinin level [<xref ref-type="bibr" rid="CR3">3</xref>]. In one aspect where ARBs can block AT II action of, ARBs seems better in protecting endothelial function. In the other aspect where ACE can booster bradykinin-NO pathway, ACEIs might be better for endothelial health (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR11">11</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Angiotensin and kinin cascades affecting nitric oxide production ARB angiotensin II receptor blocker, AT1 angiotensin type 1, AT2 angiotensin type 2, tPA tissue plasminogen activator</p></caption><graphic xlink:href="40885_2016_60_Fig1_HTML" id="MO1"/></fig>
</p><p>However, comparison of endothelial function improvement between ACEIs and ARBs has not been well studied. This study was performed to compare the effect of ACEIs or ARBs on peripheral endothelial function estimated with RHI in hypertensive patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p>This single center study was performed at Boramae Medical Center (Seoul, Korea). From January 2014 to February 2016, a total of 24 consecutive subjects with essential hypertension, aged between 35 and 80&#x000a0;years were enrolled. Additional inclusion criteria were: patients already receiving hypertensive therapy or previous untreated hypertension patients. Hypertension was defined as systolic blood pressure (BP) &#x02265;140&#x000a0;mm Hg or diastolic BP &#x02265;90&#x000a0;mm Hg or daytime systolic BP &#x02265;135&#x000a0;mm Hg or daytime diastolic BP &#x02265;85&#x000a0;mm Hg at 24&#x000a0;h BP monitoring or nighttime systolic BP &#x02265;125&#x000a0;mm Hg or nighttime diastolic BP &#x02265;75&#x000a0;mm Hg at 24&#x000a0;h BP monitoring.</p><p>Subjects with following conditions were excluded: 1) patients of serum creatinine &#x02265;1.5&#x000a0;mg/dL or during renal replacement therapy, 2) decompensated congestive heart failure, 3) systolic BP &#x0003e;180&#x000a0;mm Hg and diastolic BP &#x0003e;110&#x000a0;mm Hg, 4) acute coronary syndrome, 5) atrial fibrillation, 6) patients already receiving three-hypertensive therapy; high risk for the development of hypertensive catastrophe by cessation of medication 7) during pregnancy or planned for pregnancy subjects.</p><p>The participants were randomly assigned in a 1:1 ratio to ramipril group or telmisartan group according to a random number, generated by a web based randomization program of Medical Research Collaboration Center (MRCC) web site (<ext-link ext-link-type="uri" xlink:href="https://mrcc.snuh.org/">https://mrcc.snuh.org/</ext-link>) of our institute. The number of study patients was decided to be 24 based on the size of research fund granted by the Korean Society of Hypertension. Patients were assigned to receive ramipril 5&#x000a0;mg once a day or telmisartan 40&#x000a0;mg once a day initially. Patients already taking antihypertensive treatment discontinued previous medications during two weeks for washout. Follow-up visits occurred at four weeks and eight weeks. If BP does not reach the target BP at four weeks, upward double dose titration of drugs was prescribed to reach the target BP of less than both &#x0003c;140&#x000a0;mm Hg systolic BP and &#x0003c;90&#x000a0;mm Hg diastolic BP. And medication switched from ramipril to telmisartan, when patients complained of ACEIs induced cough.</p><p>Data were collected at three time point: Baseline (BP, PTA, inflammatory marker, lipid panel, renal panel, HbA1c and fasting serum glucose), first follow-up visit at four weeks (BP and renal panel), second follow-up visit at eight weeks (BP, PTA, inflammatory marker, lipid panel, renal panel, HbA1c and fasting serum glucose).</p><p>The study protocol was approved by the Boramae Medical Center Human Research Ethics Committee. The protocol of this study was approved by the Institutional Review Board of Boramae Medical Center. And the trial was undertaken in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient at enrollment.</p></sec><sec id="Sec4"><title>Methods for endothelial function measurement</title><p>All patients in each group underwent endothelial function test with PAT before the treatment and after 8&#x000a0;weeks treatment, respectively. The PAT (Endo-PAT2000; Itamar Medical Ltd., Caesarea, Israel) was used for non-invasive measurement of endothelial function. This system is a noninvasive technology that capture a beat-to-beat plethysmographic recording of the finger arterial pulse wave analysis (PWA) with pneumatic probes [<xref ref-type="bibr" rid="CR7">7</xref>]. PWA was performed in accordance with a protocol that described by Bonetti PO [<xref ref-type="bibr" rid="CR4">4</xref>]. Caffeine and alcohol are not allowed before PWA measurement. Each subject rested at sitting position more than 20&#x000a0;min in a quiet and thermoneutral (21&#x000a0;&#x000b0;C-24&#x000a0;&#x000b0;C) room when patients exposed cold or warm temperature before testing. Pneumatic BP cuffs were wrapped on study arm, while the other arm determined as control arm. The PAT finger probes were placed on the index finger of both hands. The reactive hyperemia procedure includes five minutes baseline recording, five minutes of blood flow occlusion through BP cuff inflation above systolic pressure and five minutes of recording after cuff deflation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>A representative reactive hyperemia arterial tonometry recording of a subject with normal reactive hyperemia index</p></caption><graphic xlink:href="40885_2016_60_Fig2_HTML" id="MO2"/></fig>
</p><p>RHI was calculated from the ratio of the average PWA during post-occlusive period compared with the average PWA during pre-occlusion baseline period. The ratio was normalized to the ratio from contralateral arm. Reproducibility of PAT was previously described by Bonetti PO [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>All numeric data are expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation for continuous variables or percentage for discrete variables. The differences in clinical characteristics and RHI were compared using the Wilcoxon-Mann&#x02013;Whitney test for continuous variable and Chi-square test and Fisher&#x02019;s exact test for discrete variables. Univariate associations between RHI and systolic BP, diastolic BP, pulse pressure (PP) and laboratory findings including lipid profile, HbA1c and inflammatory marker were evaluated using Pearson&#x02019;s bivariate correlation analysis. Scatter plots were used to show the association between the 2 continuous parameters. The significance systolic BP, diastolic BP, PP and RHI changes were examined with Wilcoxon signed-rank tests for each group. A <italic>P</italic> value of &#x0003c;0.05 is used to indicate statistical significance. All statistical tests were performed with SPSS for Windows version 22 (IBM Co., Armonk, NY, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><p>Twenty-four Eligible patients were randomized from January, 2014 to February, 2016. Of the 24 patients who entered the study, 4 patients were excluded from the analysis due to follow up loss. Therefore a total of 20 patients (83.3%) entered the analysis. There were 12 male and 8 female, ranging from 37 to 75&#x000a0;years in age. 20 consecutive patients were assigned to receive treatment with ramipril or telmisartan (<italic>n&#x02009;=</italic>&#x02009;10 per group). Baseline characteristics of this study population are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The two groups were similar in terms of demographic and baseline laboratory characteristics. But baseline systolic BP and PP were higher in telmisartan group than ramipril group (systolic BP, 159&#x02009;&#x000b1;&#x02009;6.83 vs 151&#x02009;&#x000b1;&#x02009;7.49, <italic>p&#x02009;=</italic>&#x02009;0.028; PP, 75.0&#x02009;&#x000b1;&#x02009;14.0 vs 60.3&#x02009;&#x000b1;&#x02009;12.4, <italic>p&#x02009;=</italic>&#x02009;0.034).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of study subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Total</th><th>Ramipril<break/>(<italic>n&#x02009;=</italic>&#x02009;10)</th><th>Telmisartan<break/>(<italic>n&#x02009;=</italic>&#x02009;10)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Age, years</td><td>57.9&#x02009;&#x000b1;&#x02009;11.3</td><td>55.9&#x02009;&#x000b1;&#x02009;11.2</td><td>59.8&#x02009;&#x000b1;&#x02009;11.7</td><td>0.449</td></tr><tr><td>Male, n (%)</td><td>12 (60%)</td><td>8 (80%)</td><td>4 (40%)</td><td>0.17</td></tr><tr><td colspan="5">Traditional risk factors</td></tr><tr><td>&#x02003;Diabetes mellitus, n (%)</td><td>5 (25%)</td><td>2 (20%)</td><td>3 (30%)</td><td>1.0</td></tr><tr><td>&#x02003;Current smoking, n (%)</td><td>5 (25%)</td><td>4 (40%)</td><td>1 (10%)</td><td>0.303</td></tr><tr><td>&#x02003;Systolic blood pressure, mmHg</td><td>155&#x02009;&#x000b1;&#x02009;8.04</td><td>151&#x02009;&#x000b1;&#x02009;7.49</td><td>159&#x02009;&#x000b1;&#x02009;6.83</td><td>0.028</td></tr><tr><td>&#x02003;Diastolic blood pressure, mmHg</td><td>87.2&#x02009;&#x000b1;&#x02009;12.0</td><td>90.6&#x02009;&#x000b1;&#x02009;9.00</td><td>83.7&#x02009;&#x000b1;&#x02009;14.0</td><td>0.08</td></tr><tr><td>&#x02003;Pulse pressure, mmHg</td><td>67.7&#x02009;&#x000b1;&#x02009;14.9</td><td>60.3&#x02009;&#x000b1;&#x02009;12.4</td><td>75.0&#x02009;&#x000b1;&#x02009;14.0</td><td>0.034</td></tr><tr><td>&#x02003;Mean blood pressure, mmHg</td><td>110&#x02009;&#x000b1;&#x02009;8.25</td><td>111&#x02009;&#x000b1;&#x02009;6.21</td><td>109&#x02009;&#x000b1;&#x02009;10.1</td><td>0.518</td></tr><tr><td colspan="5">Major laboratory findings</td></tr><tr><td>&#x02003;Fasting blood glucose, mg/dL</td><td>119&#x02009;&#x000b1;&#x02009;44.2</td><td>104&#x02009;&#x000b1;&#x02009;9.86</td><td>128&#x02009;&#x000b1;&#x02009;55.1</td><td>0.77</td></tr><tr><td>&#x02003;HbA1c, %</td><td>5.93&#x02009;&#x000b1;&#x02009;0.68</td><td>5.70&#x02009;&#x000b1;&#x02009;0.62</td><td>6.6</td><td>0.18</td></tr><tr><td>&#x02003;Total cholesterol, mg/dL</td><td>185&#x02009;&#x000b1;&#x02009;40.0</td><td>186&#x02009;&#x000b1;&#x02009;43.2</td><td>184&#x02009;&#x000b1;&#x02009;40.1</td><td>0.954</td></tr><tr><td>&#x02003;HDL cholesterol, mg/dL</td><td>47.7&#x02009;&#x000b1;&#x02009;9.26</td><td>47.3&#x02009;&#x000b1;&#x02009;9.37</td><td>48&#x02009;&#x000b1;&#x02009;10.0</td><td>0.936</td></tr><tr><td>&#x02003;LDL cholesterol, mg/dL</td><td>113&#x02009;&#x000b1;&#x02009;32.3</td><td>104&#x02009;&#x000b1;&#x02009;32.3</td><td>122&#x02009;&#x000b1;&#x02009;32.7</td><td>0.423</td></tr><tr><td>&#x02003;Triglyceride, mg/dL</td><td>180&#x02009;&#x000b1;&#x02009;101</td><td>163&#x02009;&#x000b1;&#x02009;93.2</td><td>197&#x02009;&#x000b1;&#x02009;114</td><td>0.521</td></tr><tr><td>&#x02003;Potassium, mmol/L</td><td>4.31&#x02009;&#x000b1;&#x02009;0.294</td><td>4.41&#x02009;&#x000b1;&#x02009;0.219</td><td>4.16&#x02009;&#x000b1;&#x02009;0.344</td><td>0.135</td></tr><tr><td>&#x02003;hs-CRP, mg/dL</td><td>0.433&#x02009;&#x000b1;&#x02009;0.825</td><td>0.085&#x02009;&#x000b1;&#x02009;0.06</td><td>1.13&#x02009;&#x000b1;&#x02009;1.27</td><td>0.364</td></tr><tr><td>&#x02003;Reactive hyperemia index</td><td>1.87&#x02009;&#x000b1;&#x02009;0.273</td><td>1.94&#x02009;&#x000b1;&#x02009;0.284</td><td>1.80&#x02009;&#x000b1;&#x02009;0.258</td><td>0.272</td></tr></tbody></table><table-wrap-foot><p>
<italic>HDL</italic> high-density lipoprotein, <italic>LDL</italic> low-density lipoprotein, hs-<italic>CRP</italic> high sensitive C-reactive protein</p></table-wrap-foot></table-wrap>
</p><p>Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> show BP, PP and their changes during the study period. In both groups, systolic and diastolic BP decreased significantly after 8&#x000a0;weeks treatment. The systolic BP ranged from 140 to 170&#x000a0;mm Hg and the diastolic BP ranged from 60 to 115&#x000a0;mm Hg at baseline. The BP was 151&#x02009;&#x000b1;&#x02009;7/91&#x02009;&#x000b1;&#x02009;9&#x000a0;mm Hg in the ramipril group and 159&#x02009;&#x000b1;&#x02009;7/84&#x02009;&#x000b1;&#x02009;14&#x000a0;mm Hg in the telmisartan group at baseline. At 8&#x000a0;weeks follow up, BP was 130&#x02009;&#x000b1;&#x02009;7/80&#x02009;&#x000b1;&#x02009;5&#x000a0;mm Hg in ramipril group and 131&#x02009;&#x000b1;&#x02009;14/73&#x02009;&#x000b1;&#x02009;9&#x000a0;mm Hg in telmisartan group. BP reduction from baseline to the 8&#x000a0;weeks follow up was 21/11&#x000a0;mm Hg (systole/diastole) in the ramipril group and 28/11&#x000a0;mm Hg (systole/diastole) telmisartan group, respectively (p value, Wilcoxon signed-rank test : 0.005, 0.012, 0.005, 0.036, respectively). The target BP (&#x0003c;140&#x000a0;mm Hg systolic and &#x0003c;90&#x000a0;mm Hg diastolic) was achieved in 9 (90%) patients in the ramipril group and 6 (60%) in the telmisartan group at 8&#x000a0;weeks follow up. PP reduced in both group (ramipril group, 60&#x02009;&#x000b1;&#x02009;12&#x000a0;mm Hg to 50&#x02009;&#x000b1;&#x02009;8&#x000a0;mm Hg; telmisartan group, 75&#x02009;&#x000b1;&#x02009;14&#x000a0;mm Hg to 57&#x02009;&#x000b1;&#x02009;15&#x000a0;mm Hg). But, change was statistically remarkable in telmisartan group, while it was borderline significant in ramipril group (<italic>p&#x02009;=</italic>&#x02009;0.066, Wilcoxon signed-rank test).<fig id="Fig3"><label>Fig. 3</label><caption><p>Systolic BP, diastolic BP, PP and reactive hyperemia index in patients at baseline and after 8&#x000a0;weeks of treatment with ramipril or telmisartan &#x02217; p&#x02009;&#x0003c;&#x02009;0.05 vs baseline</p></caption><graphic xlink:href="40885_2016_60_Fig3_HTML" id="MO3"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Blood pressure and pulse pressure before and after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameter</th><th colspan="3">Systolic blood pressure</th><th colspan="3">Diastolic blood pressure</th><th colspan="3">Pulse pressure</th></tr><tr><th>Baseline</th><th>After 8&#x000a0;weeks</th><th>
<italic>P</italic> value<sup>b</sup>
</th><th>Baseline</th><th>After 8&#x000a0;weeks</th><th>
<italic>P</italic> value<sup>b</sup>
</th><th>Baseline</th><th>After 8&#x000a0;weeks</th><th>
<italic>P</italic> value<sup>b</sup>
</th></tr></thead><tbody><tr><td>Total</td><td>155&#x02009;&#x000b1;&#x02009;8.04</td><td>130&#x02009;&#x000b1;&#x02009;11.1</td><td>&#x0003c;0.001</td><td>87.2&#x02009;&#x000b1;&#x02009;12.0</td><td>76.2&#x02009;&#x000b1;&#x02009;7.61</td><td>0.001</td><td>67.7&#x02009;&#x000b1;&#x02009;14.9</td><td>53.9&#x02009;&#x000b1;&#x02009;12.2</td><td>0.001</td></tr><tr><td>Ramipril 5&#x000a0;mg group</td><td>151&#x02009;&#x000b1;&#x02009;7.49</td><td>130&#x02009;&#x000b1;&#x02009;7.12</td><td>0.005</td><td>90.6&#x02009;&#x000b1;&#x02009;9.00</td><td>79.2&#x02009;&#x000b1;&#x02009;5.25</td><td>0.012</td><td>60.3&#x02009;&#x000b1;&#x02009;12.4</td><td>50.4&#x02009;&#x000b1;&#x02009;7.60</td><td>0.066</td></tr><tr><td>Telmisartan 40&#x000a0;mg group</td><td>159&#x02009;&#x000b1;&#x02009;6.83</td><td>131&#x02009;&#x000b1;&#x02009;14.4</td><td>0.005</td><td>83.7&#x02009;&#x000b1;&#x02009;14.0</td><td>73.1&#x02009;&#x000b1;&#x02009;8.61</td><td>0.036</td><td>75.0&#x02009;&#x000b1;&#x02009;14.0</td><td>57.4&#x02009;&#x000b1;&#x02009;15.1</td><td>0.005</td></tr><tr><td>
<italic>P</italic> value<sup>a</sup>
</td><td>0.028</td><td>0.492</td><td/><td>0.08</td><td>0.065</td><td/><td>0.034</td><td>0.363</td><td/></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Comparison between patients using ramipril and telmisartan</p><p>
<sup>b</sup>Comparison between before and after treatment</p></table-wrap-foot></table-wrap>
</p><p>Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> demonstrate the baseline and 8&#x000a0;weeks follow up RHI of both groups. The baseline RHI was 1.94&#x02009;&#x000b1;&#x02009;0.28 in ramipril group and 1.80&#x02009;&#x000b1;&#x02009;0.26 with telmisartan group (<italic>p&#x02009;=</italic>&#x02009;0.272). At 8&#x000a0;weeks follow up, the RHI was 1.64&#x02009;&#x000b1;&#x02009;0.33 in ramipril group and 1.59&#x02009;&#x000b1;&#x02009;0.46 in telmisartan group (<italic>p&#x02009;=</italic>&#x02009;0.256). During 8&#x000a0;weeks, there was no significant changes of RHI in both groups.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Reactive hyperemia index before and after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Baseline</th><th>After 8&#x000a0;weeks</th><th>
<italic>P</italic> value<sup>b</sup>
</th></tr></thead><tbody><tr><td>Total</td><td>1.87&#x02009;&#x000b1;&#x02009;0.273</td><td>1.61&#x02009;&#x000b1;&#x02009;0.393</td><td>0.014</td></tr><tr><td>Ramipril 5&#x000a0;mg group</td><td>1.94&#x02009;&#x000b1;&#x02009;0.284</td><td>1.64&#x02009;&#x000b1;&#x02009;0.331</td><td>0.083</td></tr><tr><td>Telmisartan 40&#x000a0;mg group</td><td>1.80&#x02009;&#x000b1;&#x02009;0.258</td><td>1.59&#x02009;&#x000b1;&#x02009;0.464</td><td>0.103</td></tr><tr><td>
<italic>P</italic> value<sup>a</sup>
</td><td>0.272</td><td>0.256</td><td/></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Comparison between patients using ramipril and telmisartan</p><p>
<sup>b</sup>Comparison between before and after treatment</p></table-wrap-foot></table-wrap>
</p><p>As mentioned above, the effects of 8&#x000a0;weeks of treatment on PP were more marked and significant in telmisartan group. However, despite of this favorable change of PP, telmisartan group have shown a tendency of discrepancy between changes of PP and RHI, although statistically insignificant, which means aggravation of endothelial function even with decreased PP. On the other hand, there was a positive relationship between decrease of PP after 8&#x000a0;weeks and increase of RHI in ramipril group (ramipril group, <italic>r</italic>&#x02009;=&#x02009;0.671, <italic>p&#x02009;=</italic>&#x02009;0.034; telmisartan group, <italic>r</italic>&#x02009;=&#x02009;&#x02212;0.487, <italic>p&#x02009;=</italic>&#x02009;0.153, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Association of delta pulse pressure and delta reactive hyperemia index in total patients (left), ramipril (middle) and telmisartan (right) group Delta reactive hyperemia index indicates RHI after 8&#x000a0;weeks minus RHI at baseline, and Delta PP Baseline PP minus PP after 8&#x000a0;weeks</p></caption><graphic xlink:href="40885_2016_60_Fig4_HTML" id="MO4"/></fig>
</p><p>Both medications were relatively well tolerated except one adverse event. One patient in ramipril group experienced transient global amnesia probably due to small vessel infarction. Only one patient had to change her medication from ramipril to telmisartan because of dry cough caused by ramipril.</p></sec><sec id="Sec7"><title>Discussions</title><p>The present study intended to investigate if ramipril and telmisartan affect endothelial function differently from each other after the treatment for eight weeks in hypertensive patients. During short period of treatment, while endothelial function estimated with RHI did not change in both groups. Both agents reduced systolic and diastolic blood pressure effectively without difference between two groups.</p><p>But, the effects of 8&#x000a0;weeks of treatment on PP were more marked and significant in telmisartan group. Despite these favorable hemodynamic changes, telmisartan didn&#x02019;t show improving endothelial function. Although mean RHI was stationary in ramipril group during the treatment, what extent RHI changed by is well positively correlated with changes of PP, which means the more decrease PP, the better endothelial function. However, this correlation was not seen in telmisartan group.</p><p>A few studies postulated wide PP adversely affect endothelial function [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Because any other factors associated with endothelial function such as lipid profile, smoking history, were not different between groups, the fact improvement of endothelial function is not correlated with decrease of PP in telmisartan group suggests telmisartan itself may negatively influence endothelium dependent vasodilatation.</p><p>Ramipril, a kind of ACEIs reduces the AT II level by inhibition of AT I converts to AT II, increases NO and other endothelial mediators induced by bradykinin via inhibition of kininase II, which is responsible for the degradation of bradykinin [<xref ref-type="bibr" rid="CR16">16</xref>]. Bradykinin affects vasodilatation via NO, prostacyclin and hyperpolarizing factor [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Telmisartan, a kind of ARBs inhibits the renin angiotensin system (RAS) in different way from ACEIs. ARBs bind to the AT1 receptor, interrupting its activation. As a result of AT1 receptor blockade, ARBs increase AT II concentration by a positive feedback resulting in stimulating AT II type 2 receptors (AT2Rs) as alternative pathway. AT2Rs have a role in vasodilatation by counteracting AT1 receptor mediated vasoconstriction [<xref ref-type="bibr" rid="CR18">18</xref>]. And ARBs lead to bradykinin-dependent NO release through AT2R [<xref ref-type="bibr" rid="CR19">19</xref>]. AT II binding to AT2Rs induces intracellular acidification, which activates a kininogenase. This increases production of bradykinin, which increases NO and vascular smooth muscle cell relaxation [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. But, many studies have demonstrated negative effects of persistent AT2R stimulation recently. AT2Rs mediate arterial hypertrophy, cardiac hypertrophy and fibrosis and anti-angiogenic effect on cardiovascular tissues, although it&#x02019;s uncertain if all of these changes accompany endothelial dysfunction [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>In this respect, &#x02018;ARB-acute myocardial infarction (MI) paradox&#x02019; was issued in 2004 after releasing VALUE trial. This theory focused on increase of MI in valsartan arm compared with amlodipine arm in the VALUE trial (hazard ratio&#x02009;=&#x02009;1.19, 95% CI 1.02 to 1.38, <italic>p&#x02009;=</italic>&#x02009;0.02) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Other meta-analysis of ACEIs and ARBs trials showed that ACEIs (versus placebo, non ARBs comparator and ARBs) reduced the relative risk of MI by 14% (OR 0.86, 95% CI 0.82 to 0.90, p&#x02009;&#x0003c;&#x02009;0.001), whereas ARBs (versus placebo, non ACEIs comparator and ACEIs) increased the risk of MI (OR 1.08, 95% CI 1.01 to 1.16, <italic>p&#x02009;=</italic>&#x02009;0.03) [<xref ref-type="bibr" rid="CR24">24</xref>]. Although a meta-analysis of Tsuyuki and McDonald reported that ARBs did not increase the risk of MI with OR of 1.03 (95% CI 0.93 to 1.13) compared to ACEIs, many subsequent studies disproved the results [<xref ref-type="bibr" rid="CR25">25</xref>]. The BPLTTC meta-regression analysis of 26 trials (17 trials with ACEIs and 9 trials with ARBs) showed that both ACEIs and ARBs have BP dependent risk reduction of stroke, coronary heart disease and heart failure [<xref ref-type="bibr" rid="CR26">26</xref>]. However, after adjusted for BP reduction within trials, the estimated risk reduction for coronary heart disease was 9% (3 to 14%, <italic>p&#x02009;=</italic>&#x02009;0.004), whereas ARBs do not. Furthermore, ONTARGET compared telmisartan with ramipril in patients with vascular disease or high risk diabetes [<xref ref-type="bibr" rid="CR27">27</xref>]. Telmisartan bad better BP lowering effect than ramipril, but increased MI by 7%, although statistically insignificant.</p><p>This randomized trial showed patients in both groups didn&#x02019;t show improvement of endothelial function than baseline after 8&#x000a0;week treatment, even though blood pressure reduction was enough. This finding the improvement of endothelial function and reduction of BP are not corresponding has ever been reported by Ghiadoni et al. [<xref ref-type="bibr" rid="CR28">28</xref>]. In his study, ACEIs, calcium antagonists, ARBs, and beta blockers similarly reduced BP, but only perindopril, one type of ACEI, improved endothelial function.</p><p>It&#x02019;s notable the reduction of PP is well correlated with the improvement of endothelial function expressed as a RHI not in telmisartan group, but in ramipril group. Higher PP exerts lower shear stress against arterial wall subsequently resulting in larger oxidative stress and reduced NO production [<xref ref-type="bibr" rid="CR13">13</xref>]. In telmisartan group, PP decreased significantly after treatment. However, PP reduction was not related with endothelial function improvement in telmisartan group. This finding suggests telmisartan is likely to have a prohibiting effect on endothelial functional recovery initiated by PP reduction.</p><p>Several limitations of our study should be mentioned. First, the present study is too small study to make a confirmatory conclusion regarding inferiority of telmisartan in the aspect of endothelial function. Actually, there are many studies revealing favorable effects of ARBs on endothelial function. Shuang Li et al. investigated 1737 patients of 22 trials with endothelial dysfunction, and showed that ARBs could improve endothelial function assessed by FMD compared with placebo or other hypertensive medication such as calcium channel blockers, beta-blockers and diuretics [<xref ref-type="bibr" rid="CR9">9</xref>]. But, ARBs have no significant difference with ACEIs. Other many studies show ARBs and ACEIs improved endothelial function without difference. Hornig et al. demonstrated that ACEIs and ARBs improved endothelial vasodilatation to a similar extent in coronary artery disease patients through increasing NO availability [<xref ref-type="bibr" rid="CR29">29</xref>]. Second, blood flow in cutaneous vessels is known to depend on sympathetic and autonomic nervous systems. Therefore, it is possible that changes in the finger RHI may occur due to changes in room temperature and mental status. We attempted to control these confounders by studying in a quiet and automatically thermostatic room and adjusting pulse amplitude of study arm with one of the contralateral control arm as a reference. Third, we just investigated short term effects of ACEIs and ARBs. It should be further evaluated the results shown in this study can be consistent in long term aspect.</p></sec><sec id="Sec8"><title>Conclusion</title><p>In hypertensive patients, ramipril and telmisartan reduced systolic and diastolic BP after eight weeks treatment. But, PP lowering effect was shown statistically significant only in telmisartan group. Despite PP lowering effect, telmisartan didn&#x02019;t show endothelial function improvement proportional to reduced PP. These findings suggest telmisartan may negatively influence endothelium and emphasize the role of bradykinin mediated NO production pathway in the control of endothelial function, which is saved with ramipril treatment.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACEIs</term><def><p>Angiotensin-converting enzyme inhibitors</p></def></def-item><def-item><term>ARBs</term><def><p>Angiotensin II receptor blockers</p></def></def-item><def-item><term>AT II</term><def><p>Angiotensin II</p></def></def-item><def-item><term>AT2R</term><def><p>Angiotensin II type 2 receptor</p></def></def-item><def-item><term>NO</term><def><p>Nitric oxide</p></def></def-item><def-item><term>PAT</term><def><p>Peripheral arterial tonometry</p></def></def-item><def-item><term>PWA</term><def><p>Pulse wave analysis</p></def></def-item><def-item><term>RAS</term><def><p>Renin angiotensin system</p></def></def-item><def-item><term>RHI</term><def><p>Reactive hyperemia index</p></def></def-item></def-list></glossary><ack><title>Acknowledgement</title><p>Not applicable</p><sec id="FPar1"><title>Funding</title><p>This research was supported by The Society of Korean Hypertension in 2013 (26-2013-77).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets generated during and analysed during the current study are not publicly available. Because this data will be extended to another study. But it will available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>YJK analyzed and wrote the manuscript. JBS, HLK and WHL participated in the design of the study. HYS and JY performed data collection and validated the quality of data. WYC designed the study, wrote the manuscript and gave final approval of the version to be published. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>All the co-authors gave their consent for publication.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The study was approved by our institutional review board. And we obtained informed consent from participants before study enrollment.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetti</surname><given-names>PO</given-names></name><name><surname>Lerman</surname><given-names>LO</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group><article-title>Endothelial dysfunction: a marker of atherosclerotic risk</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><issue>2</issue><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000051384.43104.FC</pub-id><pub-id pub-id-type="pmid">12588755</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerman</surname><given-names>A</given-names></name><name><surname>Sandok</surname><given-names>EK</given-names></name><name><surname>Hildebrand</surname><given-names>FL</given-names><suffix>Jr</suffix></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group><article-title>Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction</article-title><source>Circulation</source><year>1992</year><volume>85</volume><issue>5</issue><fpage>1894</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.85.5.1894</pub-id><pub-id pub-id-type="pmid">1572045</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>TJ</given-names></name></person-group><article-title>Assessment and treatment of endothelial dysfunction in humans</article-title><source>J Am Coll Cardiol</source><year>1999</year><volume>34</volume><issue>3</issue><fpage>631</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(99)00259-4</pub-id><pub-id pub-id-type="pmid">10483941</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetti</surname><given-names>PO</given-names></name><name><surname>Barsness</surname><given-names>GW</given-names></name><name><surname>Keelan</surname><given-names>PC</given-names></name><name><surname>Schnell</surname><given-names>TI</given-names></name><name><surname>Pumper</surname><given-names>GM</given-names></name><name><surname>Kuvin</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><issue>10</issue><fpage>1761</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00329-2</pub-id><pub-id pub-id-type="pmid">12767662</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Suwaidi</surname><given-names>J</given-names></name><name><surname>Hamasaki</surname><given-names>S</given-names></name><name><surname>Higano</surname><given-names>ST</given-names></name><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group><article-title>Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction</article-title><source>Circulation</source><year>2000</year><volume>101</volume><issue>9</issue><fpage>948</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.9.948</pub-id><pub-id pub-id-type="pmid">10704159</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flammer</surname><given-names>AJ</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Deanfield</surname><given-names>J</given-names></name><name><surname>Ganz</surname><given-names>P</given-names></name><etal/></person-group><article-title>The assessment of endothelial function from research into clinical practice</article-title><source>Circulation</source><year>2012</year><volume>126</volume><issue>6</issue><fpage>753</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.093245</pub-id><pub-id pub-id-type="pmid">22869857</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuvin</surname><given-names>JT</given-names></name><name><surname>Patel</surname><given-names>AR</given-names></name><name><surname>Sliney</surname><given-names>KA</given-names></name><name><surname>Pandian</surname><given-names>NG</given-names></name><name><surname>Sheffy</surname><given-names>J</given-names></name><name><surname>Schnall</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude</article-title><source>Am Heart J</source><year>2003</year><volume>146</volume><issue>1</issue><fpage>168</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0002-8703(03)00094-2</pub-id><pub-id pub-id-type="pmid">12851627</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetti</surname><given-names>P</given-names></name><name><surname>Pumper</surname><given-names>G</given-names></name><name><surname>Higano</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>D</given-names><suffix>Jr</suffix></name><name><surname>Kuvin</surname><given-names>J</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group><article-title>Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><issue>11</issue><fpage>2137</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.08.062</pub-id><pub-id pub-id-type="pmid">15582310</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Yawei</surname><given-names>X</given-names></name></person-group><article-title>Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>3</issue><fpage>e90217</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0090217</pub-id><pub-id pub-id-type="pmid">24595033</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Barker</surname><given-names>TA</given-names></name><name><surname>Berk</surname><given-names>BC</given-names></name></person-group><article-title>Angiotensin II and the endothelium: diverse signals and effects</article-title><source>Hypertension</source><year>2005</year><volume>45</volume><issue>2</issue><fpage>163</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000153321.13792.b9</pub-id><pub-id pub-id-type="pmid">15630047</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negro</surname><given-names>R</given-names></name></person-group><article-title>Endothelial effects of antihypertensive treatment: focus on irbesartan</article-title><source>Vasc Health Risk Manag</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.2147/vhrm.2008.04.01.89</pub-id><pub-id pub-id-type="pmid">18629353</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>R</given-names></name><name><surname>Dvir</surname><given-names>D</given-names></name><name><surname>Arbel</surname><given-names>Y</given-names></name><name><surname>Shechter</surname><given-names>A</given-names></name><name><surname>Feinberg</surname><given-names>MS</given-names></name><name><surname>Shechter</surname><given-names>M</given-names></name></person-group><article-title>Pulse pressure is a predictor of vascular endothelial function in middle-aged subjects with no apparent heart disease</article-title><source>Vasc Med</source><year>2010</year><volume>15</volume><issue>4</issue><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1177/1358863X10373300</pub-id><pub-id pub-id-type="pmid">20724375</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceravolo</surname><given-names>R</given-names></name><name><surname>Maio</surname><given-names>R</given-names></name><name><surname>Pujia</surname><given-names>A</given-names></name><name><surname>Sciacqua</surname><given-names>A</given-names></name><name><surname>Ventura</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Pulse pressure and endothelial dysfunction in never-treated hypertensive patients</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><issue>10</issue><fpage>1753</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(03)00295-X</pub-id><pub-id pub-id-type="pmid">12767660</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Meyer</surname><given-names>G</given-names></name><name><surname>Herman</surname><given-names>A</given-names></name></person-group><article-title>Vascular endothelial dysfunction</article-title><source>Prog Cardiovasc Dis</source><year>1997</year><volume>39</volume><issue>4</issue><fpage>325</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S0033-0620(97)80031-X</pub-id><pub-id pub-id-type="pmid">9050818</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichigi</surname><given-names>Y</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Umetani</surname><given-names>K</given-names></name><name><surname>Kawabata</surname><given-names>K</given-names></name><name><surname>Obata</surname><given-names>JE</given-names></name><name><surname>Kitta</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increased ambulatory pulse pressure is a strong risk factor for coronary endothelial vasomotor dysfunction</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>9</issue><fpage>1461</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2005.01.038</pub-id><pub-id pub-id-type="pmid">15862419</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mombouli</surname><given-names>JV</given-names></name></person-group><article-title>ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide</article-title><source>Drugs</source><year>1997</year><volume>54</volume><issue>5</issue><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.2165/00003495-199700545-00004</pub-id><pub-id pub-id-type="pmid">9429841</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>G</given-names></name><name><surname>Ebrahim</surname><given-names>Z</given-names></name></person-group><article-title>Role of bradykinin in preconditioning and protection of the ischaemic myocardium</article-title><source>Br J Pharmacol</source><year>2002</year><volume>135</volume><issue>4</issue><fpage>843</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704548</pub-id><pub-id pub-id-type="pmid">11861312</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>BI</given-names></name></person-group><article-title>How to explain the differences between renin angiotensin system modulators</article-title><source>Am J Hypertens</source><year>2005</year><volume>18</volume><issue>S5</issue><fpage>134S</fpage><lpage>41S</lpage><pub-id pub-id-type="doi">10.1016/j.amjhyper.2005.05.005</pub-id><pub-id pub-id-type="pmid">16125050</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutsumi</surname><given-names>Y</given-names></name><name><surname>Matsubara</surname><given-names>H</given-names></name><name><surname>Masaki</surname><given-names>H</given-names></name><name><surname>Kurihara</surname><given-names>H</given-names></name><name><surname>Murasawa</surname><given-names>S</given-names></name><name><surname>Takai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><issue>7</issue><fpage>925</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1172/JCI7886</pub-id><pub-id pub-id-type="pmid">10510333</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tea</surname><given-names>BS</given-names></name><name><surname>Der Sarkissian</surname><given-names>S</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Hamet</surname><given-names>P</given-names></name></person-group><article-title>deBlois D. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo</article-title><source>Hypertension</source><year>2000</year><volume>35</volume><issue>5</issue><fpage>1069</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.35.5.1069</pub-id><pub-id pub-id-type="pmid">10818066</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senbonmatsu</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Landon</surname><given-names>EJ</given-names></name><name><surname>Watanabe</surname><given-names>O</given-names></name><name><surname>Price</surname><given-names>E</given-names><suffix>Jr</suffix></name><name><surname>Roberts</surname><given-names>RL</given-names></name><etal/></person-group><article-title>A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy</article-title><source>EMBO J</source><year>2003</year><volume>22</volume><issue>24</issue><fpage>6471</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg637</pub-id><pub-id pub-id-type="pmid">14657020</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name></person-group><article-title>Angiotensin receptor blockers and myocardial infarction</article-title><source>BMJ</source><year>2004</year><volume>329</volume><issue>7477</issue><fpage>1248</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/bmj.329.7477.1248</pub-id><pub-id pub-id-type="pmid">15564232</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julius</surname><given-names>S</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Brunner</surname><given-names>HR</given-names></name><name><surname>Ekman</surname><given-names>S</given-names></name><name><surname>Hansson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9426</issue><fpage>2022</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16451-9</pub-id><pub-id pub-id-type="pmid">15207952</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>MH</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name></person-group><article-title>Angiotensin receptor blockers may increase risk of myocardial infarction unraveling the ARB-MI paradox</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>8</issue><fpage>838</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.594986</pub-id><pub-id pub-id-type="pmid">16923768</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuyuki</surname><given-names>RT</given-names></name><name><surname>McDonald</surname><given-names>MA</given-names></name></person-group><article-title>Angiotensin receptor blockers do not increase risk of myocardial infarction</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>8</issue><fpage>855</fpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.594978</pub-id><pub-id pub-id-type="pmid">16923769</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collaboration</surname><given-names>BPLTT</given-names></name></person-group><article-title>Blood pressure-dependent and independent effects of agents that inhibit the renin&#x02013;angiotensin system</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><issue>5</issue><fpage>951</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e3280bad9b4</pub-id><pub-id pub-id-type="pmid">17414657</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname><given-names>TO</given-names></name></person-group><article-title>Telmisartan, ramipril, or both in patients at high risk for vascular Events</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>15</issue><fpage>1547</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0801317</pub-id><pub-id pub-id-type="pmid">18378520</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghiadoni</surname><given-names>L</given-names></name><name><surname>Magagna</surname><given-names>A</given-names></name><name><surname>Versari</surname><given-names>D</given-names></name><name><surname>Kardasz</surname><given-names>I</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Taddei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Different effect of antihypertensive drugs on conduit artery endothelial function</article-title><source>Hypertension</source><year>2003</year><volume>41</volume><issue>6</issue><fpage>1281</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000070956.57418.22</pub-id><pub-id pub-id-type="pmid">12719441</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornig</surname><given-names>B</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Kohler</surname><given-names>C</given-names></name><name><surname>Ahlersmann</surname><given-names>D</given-names></name><name><surname>Spiekermann</surname><given-names>S</given-names></name><name><surname>Christoph</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>6</issue><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.103.6.799</pub-id><pub-id pub-id-type="pmid">11171786</pub-id></element-citation></ref></ref-list></back></article>